HIV and Influenza: Increased Risk and Severity
People with HIV (PWH) experience higher influenza incidence, severity, and complications, particularly with low CD4 counts or unsuppressed viral load.
Epidemiology
- 2-4× higher influenza incidence vs. general population
- 20-100× higher hospitalization rate (varies by CD4)
- Increased mortality: 9-170× higher (pre-ART era); still elevated with ART
- Prolonged viral shedding → increased transmission risk
Immunologic Basis
- CD4+ T-cell depletion → impaired humoral & cellular immunity
- B-cell dysfunction → reduced vaccine response, impaired neutralizing antibodies
- Mucosal immunity defects → respiratory barrier compromise
- Chronic immune activation → inflammatory dysregulation
Clinical Presentation
- Typical symptoms (fever, cough, myalgia) but often more severe/prolonged
- Higher rates of: primary viral pneumonia, secondary bacterial pneumonia (S. pneumoniae, S. aureus), exacerbations of underlying lung disease
- Atypical presentations in advanced HIV: afebrile, GI predominant, CNS involvement
Diagnosis
- Rapid influenza diagnostic tests (RIDTs): Lower sensitivity in PWH; PCR preferred
- Multiplex respiratory panels: Detect co-infections (RSV, COVID, bacteria)
- Chest imaging if pneumonia suspected
Treatment
| Agent | Dosing | Notes |
|---|---|---|
| Oseltamivir | 75mg BID ×5d (adjust for renal function) | First-line; start ≤48h ideal; still beneficial if later in severe disease |
| Zanamivir | 10mg (2 inhalations) BID ×5d | Inhaled; avoid in asthma/COPD (bronchospasm risk) |
| Peramivir | 600mg IV single dose | For hospitalized/unable to tolerate oral |
| Baloxavir | Single dose (40mg <80kg, 80mg ≥80kg) | Not studied extensively in PWH; avoid with polyvalent cations |
